cdh2 thermo fisher scientific pa5 (Thermo Fisher)
86
Structured Review
Thermo Fisher
cdh2 thermo fisher scientific pa5
Cdh2 Thermo Fisher Scientific Pa5, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdh2+thermo+fisher+scientific+pa5/pmc10033729__41467_2023_37161_MOESM1_ESM-103-297-298
Average 86 stars, based on 1 article reviews
Cdh2 Thermo Fisher Scientific Pa5, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdh2+thermo+fisher+scientific+pa5/pmc10033729__41467_2023_37161_MOESM1_ESM-103-297-298
Average 86 stars, based on 1 article reviews
cdh2 thermo fisher scientific pa5 - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Expressing:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB Mutagenesis:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB Amplification:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB Over Expression:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB Dilution Assay:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB Western Blot:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB Immunohistochemistry:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB FACS:Article Title: YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells Article Snippet: 139 HPV Status Tobacco Status Neoplasm Histologic Grade Tumor Stage Code (AJCC) Neoplasm Disease Lymph Node Stage (AJCC) YBX1 YBX1_PS102 YBX1 YBX1 YBX1_PS102 mRNA expression z-scores Protein expression z-scores 16% 4% Genetic Alteration Missense Mutation (unknown significance) Amplification mRNA High mRNA Low Protein High Protein Low No alterations HPV Status No Yes Tobacco Status No Yes Neoplasm Histologic Grade G1 G2 G3 G4 GX Tumour Stage Code (AJCC) T1 T2 T3 T4A TX No data Neoplasm Disease Lymph Node Stage (AJCC) N0 N1 N2 N2A N2B N2C N3 NX No data Expression Heatmap -3 3 Figure S8: Expression of pYBX1 and PDPN in patient HNC samples 50 100 150 PDPN 0 pYBX1 PDPN ROI % P os iti ve Ce lls 0 50 100 150 pYBX1 % Po si tiv e Ce lls pYBX1 PDPN ROI pYBX1 PDPN Patient No. (n=135) Differentiation Grading Well 51 Moderate 60 Poor 23 Ki67 0 13 1 67 2 37 3 6 4 12 p16 Negative 111 Positive 24 p53 Negative 68 Positive 48 Overexpression 19 A B C D 140 Antibody Company Catalogue No. Clone Dilution Assay Actin Abcam ab8229 1:3000 WB CDH1 Cell Signaling Technology CST3195 24E10 1:1000, 1:200 WB, IHC PDPN Abcam ab128994 EPR7072 1:1000, 1:200 WB, IHC EGFR Cell Signaling Technology CST4267 D38B1 1:1000, 1:50 WB, IHC p110 Cell Signaling Technology CST4249 C73F8 1:1000 WB p85 Cell Signaling Technology CST4257 19H8 1:1000 WB pAKT (Ser473) Cell Signaling Technology CST9271 1:1000 WB AKT Cell Signaling Technology CST9272 1:1000 WB pRPS6 (Ser240/244) Cell Signaling Technology CST2215 1:1000 WB RPS6 Cell Signaling Technology CST2217 5G10 1:1000 WB pEIF4E (Ser209) Abcam ab76256 EP2151Y 1:1000, 1:100 WB, IHC EIF4E Cell Signaling Technology CST9742 1:1000, 1:50 WB, IHC pEIF4EBP1 Cell Signaling Technology CST9451 1:1000 WB EIF4EBP1 Cell Signaling Technology CST9644 53H11 1:1000 WB |